Cagrilintide

Cagrilintide (AM833) is an acylated, long-acting analog of human amylin (IAPP) engineered for once-weekly dosing. Amylin is co-secreted with insulin from pancreatic beta cells and activates amylin receptors (AMY1–3) in the area postrema and brainstem to regulate postprandial glucose and satiety signaling. Cagrilintide is often studied in combination with semaglutide (CagriSema) as a complementary appetite-suppression approach.

Research Applications:

• Amylin receptor (AMY1-3) pharmacology studies
• Postprandial glucose and gastric emptying research
• Central appetite regulation and satiety signaling
• Combination metabolic research with GLP-1 agonists
• Beta-cell function and co-secretion studies

Key Properties:
Target: Amylin receptors AMY1–3
Structural Basis: Human amylin with fatty acid acylation
Half-life: ~7 days (subcutaneous)
CAS: 2413389-80-5

Product Specifications:
Purity: ≥98% (HPLC)
Form: Lyophilized Powder
Storage: −20 °C, protected from light

For research use only. Not for human consumption. Not for veterinary use. No medical or therapeutic claims are made. These statements have not been evaluated by the FDA.